news
AbbVie announces its new CEO
During his tenure as AbbVie’s CEO, Richard Gonzalez successfully navigated the end of exclusivity for the biologic Humira in the US.
List view / Grid view
Abbott
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
news
Moving towards the digitalisation of your lab, with the 8th edition of the Paperless Lab Academy® – this year, online
Master your eData Life Cycle is the theme of the 8th edition of the Paperless Lab Academy®, running online this year due to the pandemic.
news
FDA grants Emergency Use Authorisation to Abott’s SARS-CoV-2, influenza and RSV test
The PCR based Alinity™ m Resp-4-Plex molecular assay can detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV).
news
Antibiotics market set to generate revenue of $58,800 million by 2027
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
news
Rapid microbiology testing market set to be worth over $6 billion in 2026
Rising at a CAGR of 8.2 percent, the rapid microbiology testing market is predicted to grow over the next five years.
news
Abbott receives CE mark for COVID-19 IgG quantitative antibody blood test
The new quantitative SARS-CoV-2 IgG lab-based serology test developed by Abbott has been given the CE mark.
news
FDA approves new heart rhythm devices featuring Bluetooth connectivity and continuous remote monitoring
Abbott’s Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices are given approval.
news
‘At home’ COVID-19 antibody tests: expert opinions and manufacturer warnings
Abbott has revealed its SARS-CoV-2 antibody test was not designed for at home use despite companies selling them for this purpose. Also, what do experts think about these tests?
article
NIR In-Depth Focus 2018
This In-Depth Focus on near-infrared spectroscopy considers analysis using an innovative SAR-DRM and explores advances in technology that have an application on PAT/QbD.
news
Medtech sales to reach $522bn by 2022
EvaluateMedTech World Preview provides a range of insights into the expected performance of the medtech industry...
news
FDA approves Abbott’s molecular Zika virus test
3 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has authorised Abbott’s molecular test to detect Zika virus in whole blood (when collected alongside a patient-matched serum or plasma sample) for emergency use. This is the first molecular test made by a commercial manufacturer authorised to detect Zika in whole blood samples;…
news
FDA advisory committee adopts a positive review of Abbott’s Absorb stent
16 March 2016 | By Victoria White
Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease. It dissolves completely after 2 to 3 years...
news
Abbott to acquire diagnostics company Alere
1 February 2016 | By Victoria White
Abbott has announced that it is to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership.
news
Abbott announces positive results of its naturally dissolving stent
2 September 2015 | By Victoria White
ABSORB Japan, a trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb heart stent to Xience, has produced positive results...
news
Abbott announces positive results of its naturally dissolving stent from ABSORB Japan study
1 September 2015 | By Nick Jackson
Abbott has announced positive one-year clinical results from ABSORB Japan, a multi-center, randomised trial comparing the safety and effectiveness of Abbott's fully dissolving AbsorbTM heart stent to XIENCE®...
